Trial | NCT00970346  Report issue

Title

Safety and Efficacy of Inhaled OligoG CF-5/20 for the Treatment Cystic Fibrosis
A Randomised, Double-blind, Placebo-controlled Dose-escalation Phase I Study to Evaluate the Safety and Tolerability of Inhaled Aerosolised OligoG CF-5/20 (G-block Oligosaccharide Derived From Alginate Polysaccharide) in Healthy Volunteers

  • Phase

    Phase 1

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Study Participants

    26
Cystic fibrosis (CF) is a disease caused by a mutation in the gene that makes the cystic fibrosis transmembrane regulator protein. As a result mucus stagnation, obstruction and plugging take place in the respiratory and gastrointestinal tract, the biliary and pancreatic duct, and in the reproductive system. The objective of this study is to determine the safety and tolerability of 3 days of daily dosing of OligoG CF-5/20 versus placebo in healthy volunteers.
Study Started
Sep 30
2009
Primary Completion
Oct 31
2009
Study Completion
Nov 30
2009
Last Update
Mar 23
2016
Estimate

Drug OligoG CF-5/20

Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug

Inhaled OligoG CF-5/20 Experimental

Criteria 

Inclusion Criteria:

Healthy, male subjects aged 18 to 65 years inclusive
Normal pulmonary function; i.e. FEV1 ≥ 80% of predicted (for age, sex, height and race) and FEV1/FVC ratio ≥ 0.7
Subject's pre -study physical examination, vital signs and electrocardiogram (ECG) are normal or do not show any clinically significant abnormalities as determined by the investigator
Subject's pre - study laboratory screen are normal or, if outside of the laboratory reference range, not considered clinically significant

Exclusion Criteria:

History of any clinically relevant chronic respiratory disorder, including asthma
Current smoker or smoked within the last 12 months
History of significant drug or alcohol abuse (defined by the investigator). Subjects with a positive screen for alcohol or drugs of abuse at screening/admission will be excluded from participation in the study.
Subject who has inhaled any drug in the last 30 days prior to Day 1
Subject who has received one or more days of systemic pharmacological treatment in the 14 days immediately prior to Day 1
Participation in a New Chemical Entity clinical study within the previous 16 weeks or a marketed drug clinical study within the previous 12 weeks
Subjects with a clinically relevant history of significant hepatic, renal, endocrine, cardiac, nervous, psychiatric, gastrointestinal, pulmonary, haematological or metabolic disorder
No Results Posted